Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jan;40(1):260–262. doi: 10.1128/aac.40.1.260

TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamases.

P A Bradford 1, N V Jacobus 1, N Bhachech 1, K Bush 1
PMCID: PMC163097  PMID: 8787920

Abstract

TEM-28 (pI 6.1), expressed by an Escherichia coli clinical isolate, is a novel beta-lactamase which hydrolyzed ceftazidime, cefotaxime, and aztreonam with rates of 25, 1.1, and 5.6, respectively, relative to that for benzylpenicillin (100). The nucleotide sequence of blaTEM-28 differed from that of blaTEM-1 by two base changes, resulting in amino acid substitutions of Arg-164 to His and Glu-240 to Lys.

Full Text

The Full Text of this article is available as a PDF (225.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauernfeind A., Hörl G. Novel R-factor borne beta-lactamase of Escherichia coli confering resistance to cephalosporins. Infection. 1987 Jul-Aug;15(4):257–259. doi: 10.1007/BF01644127. [DOI] [PubMed] [Google Scholar]
  2. Bradford P. A., Cherubin C. E., Idemyor V., Rasmussen B. A., Bush K. Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate. Antimicrob Agents Chemother. 1994 Apr;38(4):761–766. doi: 10.1128/aac.38.4.761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bradford P. A., Urban C., Jaiswal A., Mariano N., Rasmussen B. A., Projan S. J., Rahal J. J., Bush K. SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother. 1995 Apr;39(4):899–905. doi: 10.1128/aac.39.4.899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bush K., Macalintal C., Rasmussen B. A., Lee V. J., Yang Y. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother. 1993 Apr;37(4):851–858. doi: 10.1128/aac.37.4.851. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bush K., Singer S. B. Effective cooling allows sonication to be used for liberation of beta-lactamases from gram negative bacteria. J Antimicrob Chemother. 1989 Jul;24(1):82–84. doi: 10.1093/jac/24.1.82. [DOI] [PubMed] [Google Scholar]
  6. Goussard S., Sougakoff W., Mabilat C., Bauernfeind A., Courvalin P. An IS1-like element is responsible for high-level synthesis of extended-spectrum beta-lactamase TEM-6 in Enterobacteriaceae. J Gen Microbiol. 1991 Dec;137(12):2681–2687. doi: 10.1099/00221287-137-12-2681. [DOI] [PubMed] [Google Scholar]
  7. Jacoby G. A., Medeiros A. A. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991 Sep;35(9):1697–1704. doi: 10.1128/aac.35.9.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mabilat C., Courvalin P. Development of "oligotyping" for characterization and molecular epidemiology of TEM beta-lactamases in members of the family Enterobacteriaceae. Antimicrob Agents Chemother. 1990 Nov;34(11):2210–2216. doi: 10.1128/aac.34.11.2210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mathew A., Harris A. M., Marshall M. J., Ross G. W. The use of analytical isoelectric focusing for detection and identification of beta-lactamases. J Gen Microbiol. 1975 May;88(1):169–178. doi: 10.1099/00221287-88-1-169. [DOI] [PubMed] [Google Scholar]
  10. Meyer K. S., Urban C., Eagan J. A., Berger B. J., Rahal J. J. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993 Sep 1;119(5):353–358. doi: 10.7326/0003-4819-119-5-199309010-00001. [DOI] [PubMed] [Google Scholar]
  11. Morosini M. I., Canton R., Martinez-Beltran J., Negri M. C., Perez-Diaz J. C., Baquero F., Blazquez J. New extended-spectrum TEM-type beta-lactamase from Salmonella enterica subsp. enterica isolated in a nosocomial outbreak. Antimicrob Agents Chemother. 1995 Feb;39(2):458–461. doi: 10.1128/aac.39.2.458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Naumovski L., Quinn J. P., Miyashiro D., Patel M., Bush K., Singer S. B., Graves D., Palzkill T., Arvin A. M. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother. 1992 Sep;36(9):1991–1996. doi: 10.1128/aac.36.9.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Palzkill T., Thomson K. S., Sanders C. C., Moland E. S., Huang W., Milligan T. W. New variant of TEM-10 beta-lactamase gene produced by a clinical isolate of proteus mirabilis. Antimicrob Agents Chemother. 1995 May;39(5):1199–1200. doi: 10.1128/aac.39.5.1199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Quinn J. P., Miyashiro D., Sahm D., Flamm R., Bush K. Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1989 Sep;33(9):1451–1456. doi: 10.1128/aac.33.9.1451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rasmussen B. A., Bradford P. A., Quinn J. P., Wiener J., Weinstein R. A., Bush K. Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 beta-lactamases encoded by different nucleotide sequences. Antimicrob Agents Chemother. 1993 Sep;37(9):1989–1992. doi: 10.1128/aac.37.9.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rice L. B., Willey S. H., Papanicolaou G. A., Medeiros A. A., Eliopoulos G. M., Moellering R. C., Jr, Jacoby G. A. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother. 1990 Nov;34(11):2193–2199. doi: 10.1128/aac.34.11.2193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sutcliffe J. G. Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3737–3741. doi: 10.1073/pnas.75.8.3737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sykes R. B., Bonner D. P., Bush K., Georgopapadakou N. H. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother. 1982 Jan;21(1):85–92. doi: 10.1128/aac.21.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Urban C., Meyer K. S., Mariano N., Rahal J. J., Flamm R., Rasmussen B. A., Bush K. Identification of TEM-26 beta-lactamase responsible for a major outbreak of ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 1994 Feb;38(2):392–395. doi: 10.1128/aac.38.2.392. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES